First MS Patients in the U.S. Receive Genzyme’s Lemtrada Following FDA Approval
By a News Reporter-Staff News Editor at Pharma Business Week– Genzyme, a Sanofi company, announced that the first U.S. patients have initiated treatment with Lemtrada ® in the commercial setting following its November 14th FDA approval for the treatment of patients with relapsing forms of multiple sclerosis. “As an investigator in the Phase III clinical…
This article is available to Insider Pro subscribers only.Sign in or register to be an Insider Pro and access ALL LOCKED articles.
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News